BOEHRINGER-INGELHEIM
14.9.2020 14:03:10 CEST | Business Wire | Press release
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint. The data showed improvement in cognition in stable adult patients with schizophrenia.1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for patients, and no pharmacological treatments are currently approved for cognitive impairment associated with schizophrenia (CIAS). These results presented at the 33rd European College of Neuropsychopharmacology (ECNP) Congress will advance the understanding of how deficits in transmission of signals between nerve cells may contribute to diminishing cognition in people living with schizophrenia.2
The Gly-T1 inhibitor, BI 425809, forms a key component of Boehringer Ingelheim’s Central Nervous System (CNS) research program. The latest trial results, along with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, will help determine the direction for BI 425809 in further schizophrenia research.3,4
Prof. W. Wolfgang Fleischhacker, Medical University Innsbruck, Austria: “The outcome of this trial is an important step forward in our understanding of cognition in schizophrenia. Cognitive impairment causes significant challenges for people in their everyday functioning. Patients with schizophrenia struggle with remembering things like birthdays, learning new tasks, concentrating, or making decisions that affect their everyday life. Advancing our understanding of how we might improve these symptoms in schizophrenia is significant for the research community and the patients and families living with this condition.”
The Phase II results of BI 425809 in cognitive impairment associated with schizophrenia are being further evaluated to assess how they will support the continued research and development for the treatment of schizophrenia.
“The trial results for our investigational compound BI 425809 in schizophrenia are encouraging. This is a positive advancement in our mechanistic knowledge of how excitatory neurotransmissions affect aspects of mental illness, aligning with our systematic neurobiological approach to CNS research,” adds Dr Vikas Mohan Sharma, M.D., head of medicine CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim. “We recognize this is important news for people affected by schizophrenia. We are making progress in developing treatments which will not only reveal important advances in our understanding of schizophrenia but also potentially other neuropsychiatric diseases.”
Cognition is a fundamental aspect of everyday life, including problem solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These functions are common to many forms of mental disorders such as schizophrenia, Alzheimer’s disease and depression. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim CNS research.
~ENDS~
For references and notes to editiors, please visit: http://www.boehringer-ingelheim.com/press-release/phase-ii-results-cognitive-impairment-schizophrenia
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ROYC Group Launches ROYC Operating System as a Standalone Enterprise Software Platform1.10.2026 09:30:00 CEST | Press release
ROYC Group today announced the launch of ROYC Operating System (ROYC OS) as a standalone software platform for fund managers, banks and wealth managers across private markets. The software is now available separately from ROYC’s existing structuring, fund operations and distribution services. Proven in production, at scale ROYC used its structuring and fund operations experience to develop its enterprise-grade digital offering that automates these services. The technology has been live in production for years, bundled with ROYC's services with more than 20 fund managers operating drawdown and evergreen funds on the ROYC OS, distributing to over 50 banks and wealth managers. “We saw where legacy solutions were failing fund managers: spreadsheets and software assembled from separate tools bolted together over time, with no single record connecting a fund to its service providers and investors,” said Octavian Popescu, Co-Founder and CEO of ROYC Group. “We built ROYC OS the other way aroun
Eaton Strengthens European Manufacturing With Expanded Production Facility in Austria1.10.2026 09:00:00 CEST | Press release
Increased capacity supports growing demand from electrification and critical infrastructure marketsNew fully automated miniature circuit breaker production and expanded low-voltage systems assembly capacity in Schrems5,000 m² facility expansion combines advanced automation, digital integration and end-to-end product traceability Eaton will celebrate the expansion of its manufacturing facility in Schrems, Austria, on 1 October 2026. The expansion supports growing demand driven by electrification and digitalisation across Europe while increasing regional manufacturing capacity for electrical protection and power management solutions. Completed in less than ten months, the expansion combines fully automated production with advanced digital integration and end-to-end product traceability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001416101/en/ Eaton expanded manufacturing capacity in Europe for power management solutions
Aegir Insights Launches Next-Generation Energy Intelligence Platform1.10.2026 09:00:00 CEST | Press release
One platform across wind, solar, storage and data centers combining commercial intelligence with investment modeling; the foundation for energy vertical AI Aegir Insights today announced the launch of its next-generation energy intelligence platform, combining commercial data, expert research and investment modeling in a single environment for investment decisions across onshore wind, offshore wind, solar, energy storage and data centers. The Aegir Platform links the intelligence that informs commercial decisions in renewables: Markets, companies, projects, auctions, supply chains and transactions. Together with analyst research and investment software, it gives the full context to assess where to invest, which assets and counterparties to consider, and what determines their viability. "Energy investment depends on understanding how projects, companies and markets fit together," said Scott Urquhart, CEO of Aegir Insights. "An asset's ownership, auction position, supply chain and route
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 08:55:00 CEST | Press release
AMRA Chief Scientific Officer Dr. Jennifer Linge will present at EASD 2026, highlighting how quantitative MRI can reveal changes in muscle that conventional measures does not fully capture. As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 08:30:00 CEST | Press release
Reorganization of Plenitude’s capital structure expands Ares’ economic and governance participation in the company Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom